Patent Granted for Piclidenoson Treatment of Rare Genetic Diseases
1 report, 1 independent
Updated Mon 00:00
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Eurasian Patent Office issued a notification of readiness to grant a patent covering the use of Piclidenoson for diseases associated with OCRL deficiency, including Lowe syndrome and Dent disease 2. Fondazione Telethon owns the patent application, and Can-Fite BioPharma Ltd. holds the rights to develop and commercialize the drug for these indications.
From manilatimes.net
Why it matters
The patent allowance strengthens the intellectual property foundation supporting the drug's development program. The drug is being studied for conditions where current management is supportive and no approved therapy addresses the underlying disease mechanism.
From manilatimes.net
Who's involved
- foundationOwns the patent application for Piclidenoson
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
-
foundation
type of nonprofit organization
-
University of Naples Federico II
university in Naples
Nothing else this week.